NCT00444951View on ClinicalTrials.gov

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 28, 2009

Conditions
Neisseria MeningitidisMeningococcal Infections
Interventions
BIOLOGICAL

Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine

0.5 mL, Intramuscular

Trial Locations (7)

Unknown

AlKhaleej

AlRabwa

S. Buraida

Safra-Al Midhnab

Helal Ahmar

Iskan

Mecca

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00444951 - Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia | Biotech Hunter | Biotech Hunter